76075-21-3

Upstream product

• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 20353-93-9 [3-(dimethylamino)-2-azaprop-2-en-1-ylidene]-dimethylammonium chloride 
• 80304-50-3 1-benzyl-5-hydroxymethylimidazole 
• 64-17-5 ethanol 
• 91025-37-5 ethyl 3-benzyl-2-sulfanylidene-2,3-dihydro-1H-imidazole-4-carboxylate 
• 1609282-78-1 1-benzyl-2-(methylthio)-5-imidazolcarbonitrile 
• 287198-16-7 3-benzyl-2-(methylsulfanyl)-3,5-dihydro-4H-imidazol-4-one 
• 39123-65-4 3-benzyl-2-thioxotetrahydro-4H-imidazol-4-one 
• 100-44-7 benzyl chloride 
• 1399859-85-8 N-benzyl-N'-(2'-acetamido)thiourea 
• 23785-21-9 1H-imidazole-5-carboxylic acid ethyl ester 
• 100-39-0 benzyl bromide 
• 76075-07-5 N-benzyl-N-formyl-glycine ethyl ester 
• 333-20-0 potassium thioacyanate 

Downstream Products

• 82830-36-2 1-Benzyl-5-(chloromethyl)-1H-imidazolium chloride 
• 5317-07-7 1-Benzylimidazole-5-carboxylic Acid 
• 85102-99-4 1-benzyl-1H-imidazole-5-carboxaldehyde 
• 80304-50-3 1-benzyl-5-hydroxymethylimidazole 

Relevant academic research and scientific papers

N-cyclopropyl methoxy imidazole amide derivative and application thereof in antitumor drugs

The invention belongs to the technical field of medicinal chemistry, and particularly relates to N-cyclopropyl methoxy imidazole amide derivatives, a preparation method and application of the N-cyclopropyl methoxy imidazole amide derivatives as an MEK inhibitor in antitumor drugs. The invention provides an N-cyclopropyl methoxy imidazole amide derivative as shown in a general formula, and geometric isomers or pharmaceutically acceptable salts, hydrates, solvates or prodrugs of the N-cyclopropyl methoxy imidazole amide derivative. The MEK inhibitor provided by the invention has specificity and effectiveness, and has a wider development prospect. Experimental results show that the N-cyclopropyl methoxy imidazole amide derivative synthesized by the research group has a prospect of developing targeted antitumor drugs.

Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists

TGR5 is emerging as an important and promising target for the treatment of diabetes, obesity and other metabolic syndromes. A series of novel 1-benzyl-1H-imidazole-5-carboxamide derivatives was designed, synthesized and evaluated in vitro and in vivo. The

Phenylethyl imidazole derivative and application thereof

The invention belongs to the technical field of medicines, and provides a novel phenylimidazole amide derivative shown as a general formula (I) (See the specification) and a geometrical isomer or pharmaceutically acceptable salt, hydrate, solvate and prodrug thereof, and preparation methods thereof. The compound can activate the activity of TGR5 and can be used for treating or preventing diseasesrelated to TGR5 activity regulation.

A Continuous-Flow Method for the Desulfurization of Substituted Thioimidazoles Applied to the Synthesis of Etomidate Derivatives

A simple yet robust flow set-up for the efficient desulfurization of a series of thioimidazoles is presented, which generates the corresponding imidazole derivatives in high yields. The strategic choice of peristaltic over piston pumps allowed reliable delivery of the heterogeneous stream of the thioimidazole substrate into a T-piece where it reacted with NaNO2 in the presence of acetic acid. This approach enabled the controlled and safe formation of the reactive nitrosonium species without uncontrolled exposure to hazardous nitrous oxide by-products as observed in related batch protocols. The value of the resulting imidazole products was further demonstrated by their conversion into various esters representing new derivatives of the known analgesic etomidate through an efficient one-pot Corey–Gilman–Ganem oxidation procedure.

Preparation of 2'-13c-l-histidine starting from 13c-thiocyanate: Synthetic access to any site-directed stable isotope enriched l-histidine

1-Benzyl-2-(methylthio)-imidazole-5-ketone is obtained in a few simple steps starting from thiocyanate and glycine amide (glycin). Subsequent treatment with diethyl phosphorocyanidate and functional group manipulations gives 1-benzyl-5-chloromethylimidazolium chloride. This compound is converted under mild O'Donnell conditions into the corresponding L-histidine derivative. After deprotection L-histidine is obtained in good yield and 99% enantiomeric excess. 2'-13C-L-Histidine has been obtained via this new scheme with high (99%) 13C incorporation starting with commercially available 13C- thiocyanate. This synthetic scheme allows access to any isotopomer of L-histidine and many other biologically important imidazole derivatives.

Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3H- cycloheptimidazol-4-ones and 2-alkyl-3H-cycloheptimidazol-4-ones

Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3H- cycloheptimidazol-4-one (1) and 2-alkyl-3H-cycloheptimidazol-4-one (2) was investigated. 3-[2′-(1-tert-Butyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2- propyl-5,6,7,8-tetrahydro-1H-cycloheptimidazol-4-one (6) was preferentially obtained under the conditions by using NaH in DMF or THF. On the other hand, 3-[2′-(1-tert-butyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2-propyl-5,6,7, 8-tetrahydro-3H-cycloheptimidazol-4-one (5), the synthetic intermediate compound of Pratosartan, was obtained selectively in the presence of n-Bu4NBr in toluene by using aqueous sodium hydroxide as a base. In this reaction, it was found that the concentration of the alkaline solution influences its regioselectivity. This selectivity was observed even for aldehyde and ester derivatives.

Novel nonprostanoid prostacyclin (PGI2) mimetics with heterocyclic moiety

Structural modification of [2-(2-benzhydryloxyiminopentyl)-1,2,3,4-tetrahydro-5-naphthyloxy]acetic acid (4), previously identified as a PGI2 agonist without a PG skeleton, was examined. Conversion of the oxime moiety in 4 to the pyrazole led to [2-(4-benzhydrylpylazoyl)methyl-1,2,3,4-tetrahydro-5-naphthyloxy]acetic acid (34) which strongly inhibited ADP-induced aggregation of human platelets in vitro.

New synthesis of 1,5-disubstituted imidazoles

A new synthesis of 1-alkylimidazole-5-carbaldehydes starting from [3- (dimethylamino)-2-azaprop-2-enylidene]dimethylammonium chloride and alkyl N- alkylglycinate is described.

Imidazole derivatives with potential biological activity

A series of 1-substituted imidazole-5-carbohydroxamic acids Ia, Ib and Ie were prepared from the corresponding 5-methoxycarbonyl imidazoles (IX) obtained by a univocal synthesis starting with the reaction of the amines (III) with ethylchloroacetate. On treatment of 4(5)-methoxycarbonyl imidazoles (XI) with alkylar halides (X), on the contrary, mixtures of 1-substituted-4(or 5)-methoxycarbonyl imidazoles were obtained that, when separated by thin-layer chromatography, gave the carbohydroxamic acids Ia, Ib, Id and Ie and IIa→f. The structures of the imidazole derivatives were obtained by means of IR, NMR and UV spectra. On carrying out tests of biological activity on these compounds, it had been found that the 5-carbohydroxamic acids possess, compared to the 4-carbohydroxamic ones, a greater activity. Particularly Ib and Ib-HCl seem fairly active against Klebsiella pneumoniae and Clostridium bifermentans, Ib-HCl against Bacillus subtilis, too.